Literature DB >> 15002789

Immunoexpression of perforin and granzyme B on infiltrating lymphocytes in human renal acute allograft rejection.

M Wagrowska-Danilewicz1, M Danilewicz.   

Abstract

Graft destruction can be effected by direct cell-to-cell contact between activated effector T cell and a target graft resulting in delivery of cytotoxic molecules. Perforin and granzyme B can be used as activation markers for cytotoxic cells in allograft tissue. The aim of the study was to determine the immunoexpression of perforin and granzyme B by immune cells infiltrating renal tissue during acute allograft rejection and to evaluate any correlation between the phenotype of infiltrating lymphocytes and cells expressing cytotoxic granules as well as the severity of graft damage as defined by Banff 97 criteria. Immunoperoxidase staining was carried out using monoclonal antibodies anti-perforin, -granzyme B, -CD3 and -CD8 on renal allograft biopsy specimens from twenty one patients with acute renal transplant rejection: Banff 97 IA (n = 11) and Banff 97 IB (n = 10). As a control 11 biopsy specimens of renal transplant patient without any signs of rejection were used. All allograft biopsy specimens with acute renal transplant rejection contained a high number of CD3+ T cells (Banff IA: 437.4 +/- 154.4 and Banff IB: 825 +/- 339.9 vs 123.4 +/- 52.5 in controls) and CD8+ T lymphocytes (Banff 97 IA: 177.6 +/- 89.2 and Banff IB: 293.2 +/- 112.4 vs 64.2 +/- 37.1 in controls). Immunostaining for granzyme B and perforin was negative in controls. The immunopositivity for perforin was similar in Banff IA and Banff IB acute allograft rejection (1.5 +/- 0.6 vs 1.8 +/- 0.8, respectively). Granzyme B+ cell count was significantly higher in severe rejection group Banff IB (128.3 +/- 74.3) than in Banff IA group (48.2 +/- 18.3). Moreover, in acute allograft rejection Banff IB the number of granzyme B+ cells and perforin+ cells was correlated with the number of CD8+ T cells. In conclusion, our results suggest that in acute tubulointerstitial allograft rejection activated cytotoxic T lymphocytes play a major role. The strong immunopositivity for granzyme B on infiltrating cells in renal transplant tissue is suggested as a marker of severity of graft damage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15002789

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  6 in total

1.  Cytotoxic T Lymphocytes (CTLs) and Kidney Transplantation: An Overview.

Authors:  Federica Rascio; Paola Pontrelli; Giuseppe Grandaliano
Journal:  Methods Mol Biol       Date:  2021

2.  Non-invasive messenger RNA transcriptional evaluation in human kidney allograft dysfunction.

Authors:  G Joelsons; T Domenico; L F Gonçalves; R C Manfro
Journal:  Braz J Med Biol Res       Date:  2018-05-17       Impact factor: 2.590

3.  Investigation of Cytotoxic T Lymphocyte Function during Allorejection in the Anterior Chamber of the Eye.

Authors:  Hsin-Fang Chang; Marie-Louise Wirkner; Elmar Krause; Jens Rettig
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

4.  Non-invasive early detection of acute transplant rejection via nanosensors of granzyme B activity.

Authors:  Quoc D Mac; Dave V Mathews; Justin A Kahla; Claire M Stoffers; Olivia M Delmas; Brandon Alexander Holt; Andrew B Adams; Gabriel A Kwong
Journal:  Nat Biomed Eng       Date:  2019-02-18       Impact factor: 25.671

5.  Histopathological analysis of infiltrating T cell subsets in acute T cell-mediated rejection in the kidney transplant.

Authors:  Francisco Salcido-Ochoa; Susan Swee-Shan Hue; Siyu Peng; Zhaoxiang Fan; Reiko Lixiang Li; Jabed Iqbal; John Carson Allen; Alwin Hwai Liang Loh
Journal:  World J Transplant       Date:  2017-08-24

6.  Single-Cell RNA Sequencing Reveals the Immunological Profiles of Renal Allograft Rejection in Mice.

Authors:  Qixia Shen; Yucheng Wang; Jiaoyi Chen; Lifeng Ma; Xiaoru Huang; Sydney C W Tang; Huiyao Lan; Hong Jiang; Jianghua Chen
Journal:  Front Immunol       Date:  2021-07-22       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.